Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus fermentum CQPC04
- Development stage
- Preclinical
- Lead developer
- The First People's Hospital of Kunshan
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus fermentum* CQPC04 is a specific probiotic bacterial strain originally isolated from traditional Sichuan pickles (Paocai). It is being researched for its potential therapeutic applications in metabolic disorders, particularly hyperlipidemia and hyperglycemia. The strain functions by modulating the gut microbiota and influencing systemic metabolic pathways. Research indicates that CQPC04 activates the AMPK (AMP-activated protein kinase) and SIRT1 (Sirtuin 1) signaling pathways, which in turn regulates the expression of genes involved in lipid metabolism, such as PPAR-α (Peroxisome proliferator-activated receptor alpha) and LXR-α (Liver X receptor alpha). In preclinical models, administration of this strain has been shown to significantly reduce total cholesterol, triglycerides, and blood glucose levels while improving antioxidant capacity and reducing inflammation. The development is primarily associated with research institutions in China, including The First People's Hospital of Kunshan and Chongqing University of Education.
- Other names
- L. fermentum CQPC04Lactobacillus fermentum strain CQPC04
02
Targets
SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)
Beyond the preview
Go deeper on Lactobacillus fermentum CQPC04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus fermentum CQPC04.